In June 2020, Janssen Pharmaceuticals changed the warnings on the product label for the U.S. versions of interstitial cystitis (IC) drug Elmiron (pentosan polysulfate sodium or PPS). The new warnings alerted doctors and patients to the potential risk of vision damage. Many American consumers, however,…
Retinal vasculitis is an inflammatory condition affecting the blood vessels in the retina of the eye. It usually occurs in association with another disease like lupus or Behcet’s syndrome, but recent studies suggest it may also be associated with the prescription drug Beovu (brolucizumab), which…
In June 2019, online pharmacy Valisure detected a cancer-causing agent (NDMA) in the popular heartburn drug Zantac (ranitidine). Since then, thousands of consumers have been concerned that if they took the drug—particularly if they took it for long periods—they may now be at an increased…
When Bayer announced in July 2018 that it would stop selling the permanent birth control device Essure, the U.S. Food and Drug Administration (FDA) required the company to continue to evaluate long-term safety information in women who received the device. According to the latest analysis…
A Florida man has recently joined the Zantac MDL proceeding in the U.S. District Court for the District of Southern Florida. He filed a short-form complaint alleging that he developed cancer after using Zantac for several years. The U.S. Judicial Panel on Multidistrict Litigation (JPML)…
In June 2020, Janssen Pharmaceuticals, which manufactures the interstitial cystitis (IC) drug Elmiron, updated the warning label on the medication, alerting patients and doctors of the potential risk of vision damage. Unfortunately, there is evidence that suggests that the drug manufacturer knew or should have…
The U.S. Food and Drug Administration (FDA) approved the prescription drug Beovu (brolucizumab-dbll) in October 2019 for the treatment of wet age-related macular degeneration (AMD), a serious eye disease. Recent research, however, has suggested that patients taking the drug may have a slightly increased risk…
On September 12, 2019, the FDA first alerted the public to the possible presence of cancer-causing N-nitrosodimethylamine (NDMA) in Zantac and generic ranitidine medications. Since then, drug manufacturers have faced an increasing number of Zantac lawsuits filed against them in courts across the country. Now,…
On April 1, 2020, the U.S. Food and Drug Administration (FDA) requested the recall of all Zantac (ranitidine) antacid products from the market. Many of the products had tested positive for unsafe levels of N-nitroso dimethylamine (NDMA), a cancer-causing substance. Following that recall, many individuals…
On July 13, 2018, the U.S. Food and Drug Administration (FDA) alerted healthcare professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan, which is used to treat high blood pressure and heart failure. An impurity called N-nitrosodimethylamine (NDMA)—a…
